The Cardio-renal patient: A holistic approach to achieving Excellence in Primary Care

Our study days are sponsored by pharmaceutical companies, who provide funding that allows us to offer all events completely free of charge. Sponsors have no involvement in agenda development, speaker selection, or clinical content – this is managed entirely by MORPh’s clinical team.

The “The Cardio-renal patient: A holistic approach to achieving Excellence in Primary Care”  Study Day is free to access for all registered healthcare professionals that have a MORPh Account.

Doors will open at 09:00 for welcome and introductions the study day will begin shortly after. Our expert speakers will be discussing the following topics:

Learning Objectives 

By the end of today’s session, delegates will be able to: 

• Understand key cardiometabolic risk factors and interpret tools such as QRISK3 to guide prevention and treatment decisions. 
• Apply NICE‑aligned management strategies for hypertension, including medicine selection, optimisation, and monitoring. 
• Interpret lipid profiles and initiate/optimise evidence‑based lipid‑lowering therapies for ASCVD prevention. 
• Identify and manage cardiorenal metabolic issues, including CKD staging, renoprotective therapy, and referral thresholds. 

Hypertension and CV Risk Foundations

Cardiometabolic Risk – Foundations (an overview) 

• Understanding cardiometabolic disease pathways 
• Risk factors: metabolic syndrome, obesity, ethnicity, lifestyle 
• QRISK3 and primary prevention strategies 

Hypertension – Practical Management 

• Diagnosing hypertension (clinic, ABPM, HBPM) 
• Choosing pharmacotherapy by age, ethnicity, comorbidities 
• Hypertensive urgency vs emergency 
• Monitoring, follow up, and deprescribing when needed 

Interactive task: Optimise therapy for two mock patient cases.

Lipid Management & ASCVD Prevention

• Understanding lipid profiles (LDL C, non HDL, triglycerides) 
• Statins, ezetimibe, bempedoic acid, inclisiran 
• Managing high triglycerides and secondary causes 
• Primary vs secondary prevention pathways 
• When to escalate or refer 

Activity: Design a lipid lowering plan for three different profiles.

CKD & Cardiorenal Metabolic Care

• Staging CKD (eGFR, ACR) 
• Renoprotective therapies (ACEi/ARB, SGLT2i) 
• Avoiding nephrotoxic risk 
• Managing hypertension and diabetes in CKD 
• When to refer to renal services 
• Mini workshop: Optimise therapy for a patient with diabetes + CKD stage 3b. 

Type 2 Diabetes: 2026 Guideline Updates – CPD Accredited

By the end of this session, participants will be able to: 

• Understand the latest 2026 guidelines to support evidence-based clinical decision making in type 2 diabetes  
• Apply guideline recommendations to select and sequence therapies tailored to individual patient needs in primary care  
• Feel confident initiating and optimising medication, including safe titration and intensification in routine practice  
• Interpret key monitoring parameters (e.g. HbA1c, renal function) during follow-up and recognise expected vs. suboptimal responses  
• Manage common clinical challenges, including adverse effects, comorbidities, and when to escalate treatment or refer to specialist care